ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. The company's lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. Its other product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple precision medicines targeting other cancer resistance mechanisms. It has collaboration and license agreement with Astellas Pharma, Inc.; Voronoi, Inc.; and Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
IPO Year: 2020
Exchange: NASDAQ
Website: oricpharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/8/2025 | $15.00 | Buy | Ladenburg Thalmann |
| 10/31/2024 | $20.00 | Overweight | Wells Fargo |
| 9/6/2024 | $20.00 | Buy | Stifel |
| 2/23/2024 | Overweight | Cantor Fitzgerald | |
| 9/22/2023 | $8.00 | Outperform | Wedbush |
| 3/23/2023 | $16.00 | Neutral → Buy | H.C. Wainwright |
| 3/21/2023 | $15.00 | Neutral → Buy | Guggenheim |
| 3/16/2023 | $14.00 | Perform → Outperform | Oppenheimer |
| 7/18/2022 | Perform | Oppenheimer | |
| 4/4/2022 | $7.00 → $10.00 | Neutral → Buy | Citigroup |
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)
4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)
4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)
4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)
4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)
4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)
4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)
4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)
4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)
4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Fastest customizable press release news feed in the world
SCHEDULE 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)
10-Q - Oric Pharmaceuticals, Inc. (0001796280) (Filer)
8-K - Oric Pharmaceuticals, Inc. (0001796280) (Filer)
SCHEDULE 13G - Oric Pharmaceuticals, Inc. (0001796280) (Subject)
424B3 - Oric Pharmaceuticals, Inc. (0001796280) (Filer)
EFFECT - Oric Pharmaceuticals, Inc. (0001796280) (Filer)
8-K - Oric Pharmaceuticals, Inc. (0001796280) (Filer)
S-3 - Oric Pharmaceuticals, Inc. (0001796280) (Filer)
144 - Oric Pharmaceuticals, Inc. (0001796280) (Subject)
D - Oric Pharmaceuticals, Inc. (0001796280) (Filer)
Ladenburg Thalmann initiated coverage of ORIC Pharmaceuticals with a rating of Buy and set a new price target of $15.00
Wells Fargo initiated coverage of ORIC Pharmaceuticals with a rating of Overweight and set a new price target of $20.00
Stifel initiated coverage of ORIC Pharmaceuticals with a rating of Buy and set a new price target of $20.00
Cantor Fitzgerald initiated coverage of ORIC Pharmaceuticals with a rating of Overweight
Wedbush initiated coverage of ORIC Pharmaceuticals with a rating of Outperform and set a new price target of $8.00
H.C. Wainwright upgraded ORIC Pharmaceuticals from Neutral to Buy and set a new price target of $16.00
Guggenheim upgraded ORIC Pharmaceuticals from Neutral to Buy and set a new price target of $15.00
Oppenheimer upgraded ORIC Pharmaceuticals from Perform to Outperform and set a new price target of $14.00
Oppenheimer resumed coverage of ORIC Pharmaceuticals with a rating of Perform
Citigroup upgraded ORIC Pharmaceuticals from Neutral to Buy and set a new price target of $10.00 from $7.00 previously
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of Kevin Brodbeck, PhD, to the newly established role of Chief Technical Officer (CTO). Dr. Brodbeck brings more than 25 years of experience leading technical operations, quality assurance, chemistry, manufacturing and controls (CMC), and regulatory activities across a wide range of pharmaceutical products at all stages of development and commercialization. The creation of the CTO role and Dr. Brodbeck's appointment reflect t
Reported potentially best-in-class clinical efficacy and safety data from ongoing Phase 1b trial of ORIC-944 in combination with AR inhibitors for the treatment of patients with mCRPC Strengthened cash position with $244 million gross proceeds from top-tier healthcare specialist investors across $125 million private placement financing and $119 million ATM issuances; Following recent financing activity, ORIC concludes anticipated ATM facility usage In anticipation of potential initiation of registrational trials in 2026 for ORIC-944 and ORIC-114 (enozertinib), the company has revised its operating plan to substantially reduce investment in discovery research Under the revised operating
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 01, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on August 1, 2025 (the "Grant Date"), ORIC granted a total of 35,000 non-qualified stock options and 5,800 restricted stock units to two new non-executive employees who began their employment with ORIC in July 2025. These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient's continued employment or service through each applicable vesting date. The stock o
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, July 03, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on July 1, 2025 (the "Grant Date"), ORIC granted a total of 9,000 non-qualified stock options and 1,600 restricted stock units to one new non-executive employee who began their employment with ORIC in June 2025. These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient's continued employment or service through each applicable vesting date. The stock
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 06, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on June 2, 2025 (the "Grant Date"), ORIC granted a total of 39,100 non-qualified stock options and 6,500 restricted stock units to three new non-executive employees who began their employment with ORIC in May 2025. These inducement grants were granted pursuant to the ORIC Pharmaceuticals, Inc. 2022 Inducement Equity Incentive Plan, subject to recipient's continued employment or service through each applicable vesting date. The stock op
Financing led by SR One and includes participation from new and existing investors, including Point72, Viking Global Investors, Venrock Healthcare Capital Partners, New Enterprise Associates (NEA), Nextech, Vivo Capital, and NEXTBio Capital Pro forma cash and investments expected to fund current operating plan into the second half of 2027 and through anticipated primary endpoint readout from first ORIC-944 Phase 3 registrational trial in prostate cancer SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, to
Broad and deep PSA responses achieved, with 59% PSA50 response rate (confirmed rate of 47%, and one additional response pending confirmation) and 24% PSA90 response rate (all confirmed) in patients with mCRPC PSA responses were observed across all ORIC-944 dose levels and at comparable rates in combination with apalutamide and with darolutamide; majority of patients are still ongoing with multiple patients approaching one year or more Both combination regimens demonstrated a safety profile compatible with long term dosing, with the vast majority of adverse events Grade 1 or 2 Announced concurrent $125 million financing, which extends cash runway into 2H 2027 and through anticipated
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in June: Jefferies Global Healthcare Conference – Participating in a fireside chat on Wednesday, June 4, 2025, at 12:50 p.m. ETGoldman Sachs 46th Annual Global Healthcare Conference – Participating in a fireside chat on Tuesday, June 10, 2025, at 10:00 a.m. ET Webcasts of the discussions will be available through the investor section of the company's website at www.oricp
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that the company will present initial data from the Phase 1b trial of ORIC-944 in combination with androgen receptor inhibitors in patients with metastatic castration resistant prostate cancer (mCRPC) in a conference call and webcast on Wednesday, May 28, 2025, at 4:30 p.m. ET. To join the conference call via phone and participate in the live Q&A session, please pre-register online here to receive a telephone number and unique passcode req
Announced focused registrational clinical development plans for lead programs, extended cash runway, and accelerated/augmented corporate milestones Presented preclinical data supporting potential best-in-class profile of ORIC-944 in combination with AR inhibitors to treat prostate cancer at the 2025 AACR Annual Meeting Announced clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC-114 in combination with subcutaneous amivantamab for the first-line treatment of NSCLC patients with EGFR exon 20 insertion mutations Expects to report five data readouts across ORIC-944 and ORIC-114 clinical programs over the next 15 months, with potential initiation of regi
This live feed shows all institutional transactions in real time.
SC 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)
SC 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)
SC 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)
SC 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)
SC 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)
SC 13G - Oric Pharmaceuticals, Inc. (0001796280) (Subject)
SC 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)
SC 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)
SC 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)
SC 13G/A - Oric Pharmaceuticals, Inc. (0001796280) (Subject)
Live Leadership Updates
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of Kevin Brodbeck, PhD, to the newly established role of Chief Technical Officer (CTO). Dr. Brodbeck brings more than 25 years of experience leading technical operations, quality assurance, chemistry, manufacturing and controls (CMC), and regulatory activities across a wide range of pharmaceutical products at all stages of development and commercialization. The creation of the CTO role and Dr. Brodbeck's appointment reflect t
Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with androgen receptor inhibitors in patients with mCRPC Entered into clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC-114 in combination with subcutaneous amivantamab for the first-line treatment of NSCLC patients with EGFR exon 20 insertion mutations Expects to report seven data readouts across ORIC-114 and ORIC-944 clinical programs over the next 18 months, with potential initiation of registrational trials in 2H25 and early 2026 Cash and investments of $256 million expected
Announces encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with apalutamide in patients with mCRPC Entered into clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC-114 in combination with subcutaneous amivantamab for the first-line treatment of NSCLC patients with EGFR exon 20 insertion mutations Expects to report seven data readouts across ORIC-114 and ORIC-944 clinical programs over the next 18 months, with potential initiation of registrational trials in 2H25 and early 2026 Cash and investments expected to fund operating plan into late 2026 SOUTH SAN FRANCISCO and SAN DIEGO, J
Presented preclinical data further supporting the potential best-in-class profile of ORIC-114 to treat EGFR exon 20 insertions and other atypical mutations at the EORTC-NCI-AACR Conference Announced clinical collaborations with multiple strategic partners to support ongoing trial evaluating ORIC-944 in combination with AR inhibitors for the treatment of prostate cancer Cash and investments of $282.4 million expected to fund operating plan into late 2026 SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resis
SAN FRANCISCO, Sept. 17, 2024 /PRNewswire/ -- OpenBench, Inc., a pioneer in AI-enabled success-driven small molecule discovery partnerships, today announced the launch of a collaboration with ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance. The parties aim to apply OpenBench's success-driven discovery approach and structure-based machine learning platform to enrich early discovery efforts against an undisclosed target identified by ORIC's resistance platform to target cancer-specific vulnerabilities.
Initiated dosing of ORIC-944 in combinations with NUBEQA® (darolutamide) and ERLEADA® (apalutamide) in the ongoing Phase 1b trial for prostate cancer Entered into clinical trial collaboration and supply agreements with Bayer and Johnson & Johnson to support the ongoing Phase 1b trial of ORIC-944 in combination with NUBEQA® and in combination with ERLEADA® Expanded leadership team with the appointment of industry veteran Keith Lui as Senior Vice President of Commercial and Medical Affairs Cash and investments of $308.5 million expected to fund operating plan into late 2026 SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals,
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs. "We are thrilled to welcome Keith to the ORIC leadership team," said Jacob M. Chacko, M.D., president and chief executive officer. "Keith's exceptional multi-decade track record of helping to bring innovative therapies to market, combined with his experience in strategic planning and medical affairs, will be invaluable as we advance our differentiated p
SAN DIEGO and BASEL, Switzerland, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a biotechnology company developing next-generation cytokine immunotherapies to treat cancer and autoimmune disease, today announced that it has appointed Jacob Chacko, M.D., as Chair of its Board of Directors. Dr. Chacko currently serves as President, CEO and member of the Board of Directors of ORIC Pharmaceuticals, Inc., (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance. "Jacob is an accomplished life-science executive and highly regarded board member with a track record of building leading oncology-focused biotech
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of Angie You, Ph.D., to its board of directors. Dr. You currently serves as chief executive officer of Amunix Pharmaceuticals, Inc. "We are delighted to welcome Angie to ORIC's board of directors," said Jacob Chacko, M.D., president and chief executive officer. "Angie's broad experience spanning venture capital, a variety of business development transactions, and public company leadership will bring valuable expertise and in
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 16, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the appointment of 25-year industry veteran Steven L. Hoerter to its Board of Directors. "We are thrilled to welcome Steve to ORIC's board of directors," said Jacob Chacko, M.D., president and chief executive officer. "Over a multi-decade career spanning executive roles in sales, marketing, commercial, and public company leadership, Steve has amassed deep experience at leading oncology companies, including Genentech, Agios, and Deciphera. W
Live finance-specific insights
Broad and deep PSA responses achieved, with 59% PSA50 response rate (confirmed rate of 47%, and one additional response pending confirmation) and 24% PSA90 response rate (all confirmed) in patients with mCRPC PSA responses were observed across all ORIC-944 dose levels and at comparable rates in combination with apalutamide and with darolutamide; majority of patients are still ongoing with multiple patients approaching one year or more Both combination regimens demonstrated a safety profile compatible with long term dosing, with the vast majority of adverse events Grade 1 or 2 Announced concurrent $125 million financing, which extends cash runway into 2H 2027 and through anticipated
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that the company will present initial data from the Phase 1b trial of ORIC-944 in combination with androgen receptor inhibitors in patients with metastatic castration resistant prostate cancer (mCRPC) in a conference call and webcast on Wednesday, May 28, 2025, at 4:30 p.m. ET. To join the conference call via phone and participate in the live Q&A session, please pre-register online here to receive a telephone number and unique passcode req
Preliminary evidence of clinical antimyeloma activity, including reduction in paraprotein, demonstrated in multiple patients Clean safety profile with only Grade 1 and 2 treatment related adverse events and no dose limiting toxicities or dose reductions Clinical activity, safety profile, and dose-dependent increases in immune cell activation support potential for combination studies with other multiple myeloma agents, including BCMA- and CD38-directed therapies Company to pursue strategic partnership for combination studies, resulting in extension of cash runway into 2026 Company to host conference call and webcast today at 4:30 pm ET SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 11
CNS activity observed at multiple dose levels, including the first reported confirmed CNS complete response by an EGFR exon 20 inhibitor in a patient with documented untreated brain metastases Systemic responses observed at multiple dose levels in heavily pre-treated NSCLC patients, characterized by 81% having received prior EGFR exon 20 targeted agents and 86% having CNS metastases at baseline At potential RP2D of 75 mg QD, responses observed in 2 of 3 EGFR exon 20 patients previously treated with amivantamab (67% ORR), including a confirmed complete response Responses observed at multiple dose levels in HER2 exon 20 patients, including a partial response with 100% target lesion
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that the company will present two poster presentations at the European Society of Medical Oncology (ESMO) Congress 2023 taking place October 20-24, 2023, in Madrid, Spain. The presentations will highlight the initial Phase 1b clinical data for ORIC-114 in EGFR/HER2 exon 20 mutated cancers and new preclinical data for ORIC-114 demonstrating activity against additional atypical mutations in EGFR. In conjunction with the ESMO presentations, OR
Announces decision to discontinue development of ORIC-101 Company will focus on advancing its three single agent Phase 1 programs, ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2 cancers, and ORIC-944 in prostate cancer, with initial data expected from the three programs in 1H 2023 With cash and investments of $280.4 million, cash runway extended into 2H 2024 Conference call and webcast today at 5:00 p.m. ET SOUTH SAN FRANCISCO Calif. and SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced the discontinuation of
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 17, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will host a conference call and webcast to discuss its fourth quarter and full year 2021 financial results and provide an operational update on Monday, March 21, 2022, at 5:00 p.m. ET. Webcast and Conference Call To participate in the conference call, please dial (833) 651-0991 (domestic) or (918) 922-6080 (international) and refer to conference ID 8637367. A live webcast and audio archive of the conference call will be a
CD73 inhibition overcomes immunosuppression and demonstrates activity in assays derived from relapsed or refractory multiple myeloma patients, offering the potential for single agent activity in the clinic Phase 1 trial of single agent ORIC-533, a highly potent, orally bioavailable small molecule inhibitor of CD73, expected to initiate in 4Q 2021 in patients with multiple myeloma Conference call and webcast today at 5:30 p.m. ET SOUTH SAN FRANCISCO and SAN DIEGO, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance presented preclinical dat
Call to discuss poster presentation on ORIC CD73 inhibitor in human ex vivo multiple myeloma systems presented at the American Society of Hematology (ASH) Annual Meeting Senior author Dr. Kenneth Anderson to discuss beneficial effects of ORIC CD73 inhibitor on restoring human antitumor immunity in multiple myeloma Webcast event scheduled for Monday, December 13, 2021, at 5:30 p.m. ET SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 09, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that the company will host a conference call and webcas
ORIC-101 and enzalutamide combination regimen at the recommended Phase 2 dose was well tolerated; adverse events generally consistent with single agent enzalutamide ORIC-101 plasma concentrations provided excellent target coverage, consistent suppression of key glucocorticoid receptor (GR) biomarkers, and no evidence of drug-drug interaction impacting enzalutamide The addition of ORIC-101 after progression on single agent enzalutamide enabled continued enzalutamide treatment, with preliminary evidence of longer time on treatment demonstrated in a key patient population with tumors having moderate to high GR versus low GR expression ORIC-114 demonstrated compelling brain exposure and